KR101423284B1 - 위 음식물 수용능 장해 치료약 - Google Patents

위 음식물 수용능 장해 치료약 Download PDF

Info

Publication number
KR101423284B1
KR101423284B1 KR1020137022604A KR20137022604A KR101423284B1 KR 101423284 B1 KR101423284 B1 KR 101423284B1 KR 1020137022604 A KR1020137022604 A KR 1020137022604A KR 20137022604 A KR20137022604 A KR 20137022604A KR 101423284 B1 KR101423284 B1 KR 101423284B1
Authority
KR
South Korea
Prior art keywords
group
stomach
compound
food
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020137022604A
Other languages
English (en)
Korean (ko)
Other versions
KR20130101162A (ko
Inventor
유고 마츠나가
시게루 우에키
라이타 히가시노
마사나오 가와치
히로키 가토
시로 고바야시
Original Assignee
제리아 신야쿠 고교 가부시키 가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28786350&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101423284(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 제리아 신야쿠 고교 가부시키 가이샤 filed Critical 제리아 신야쿠 고교 가부시키 가이샤
Publication of KR20130101162A publication Critical patent/KR20130101162A/ko
Application granted granted Critical
Publication of KR101423284B1 publication Critical patent/KR101423284B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020137022604A 2002-04-08 2003-04-08 위 음식물 수용능 장해 치료약 Expired - Lifetime KR101423284B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002104894 2002-04-08
JPJP-P-2002-104894 2002-04-08
PCT/JP2003/004445 WO2003084537A1 (en) 2002-04-08 2003-04-08 Therapeutic agent for food competence disorder in stomach

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020127005319A Division KR20120037035A (ko) 2002-04-08 2003-04-08 위 음식물 수용능 장해 치료약

Publications (2)

Publication Number Publication Date
KR20130101162A KR20130101162A (ko) 2013-09-12
KR101423284B1 true KR101423284B1 (ko) 2014-07-24

Family

ID=28786350

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020137022604A Expired - Lifetime KR101423284B1 (ko) 2002-04-08 2003-04-08 위 음식물 수용능 장해 치료약
KR10-2004-7015764A Ceased KR20050002925A (ko) 2002-04-08 2003-04-08 위 음식물 수용능 장해 치료약
KR1020127005319A Ceased KR20120037035A (ko) 2002-04-08 2003-04-08 위 음식물 수용능 장해 치료약
KR1020117000220A Ceased KR20110010837A (ko) 2002-04-08 2003-04-08 위 음식물 수용능 장해 치료약

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR10-2004-7015764A Ceased KR20050002925A (ko) 2002-04-08 2003-04-08 위 음식물 수용능 장해 치료약
KR1020127005319A Ceased KR20120037035A (ko) 2002-04-08 2003-04-08 위 음식물 수용능 장해 치료약
KR1020117000220A Ceased KR20110010837A (ko) 2002-04-08 2003-04-08 위 음식물 수용능 장해 치료약

Country Status (14)

Country Link
US (4) US20050176788A1 (enExample)
EP (2) EP2301540A1 (enExample)
JP (2) JP5281226B2 (enExample)
KR (4) KR101423284B1 (enExample)
CN (2) CN102125551B (enExample)
AT (1) ATE522214T1 (enExample)
AU (1) AU2003236326B2 (enExample)
CA (1) CA2481916C (enExample)
CY (1) CY1112057T1 (enExample)
DK (1) DK1493441T3 (enExample)
ES (1) ES2368732T3 (enExample)
PT (1) PT1493441E (enExample)
SI (1) SI1493441T1 (enExample)
WO (1) WO2003084537A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104447612A (zh) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 阿考替胺水合物晶型及其制备方法和用途
CN103980226A (zh) * 2014-05-10 2014-08-13 杭州新博思生物医药有限公司 盐酸阿考替胺水合物晶型及其制备方法
CN105315225A (zh) * 2014-07-07 2016-02-10 中美华世通生物医药科技（武汉）有限公司 阿考替胺的酸加成盐及其制备方法
CN104045606B (zh) * 2014-07-11 2015-09-30 杭州新博思生物医药有限公司 一锅法制备阿考替胺盐酸盐的方法
CN109988121B (zh) * 2019-04-28 2023-01-03 梯尔希（南京）药物研发有限公司 一种阿考替胺衍生物的制备方法
MX2024000751A (es) 2021-07-14 2024-03-25 Blueprint Medicines Corp Compuestos heterociclicos como inhibidores de map4k1.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2219747C (en) * 1995-05-18 2008-11-25 Zeria Pharmaceutical Co., Ltd. Aminothiazole derivative, medicament containing the same, and intermediate for preparation of said compound
JPH10212271A (ja) * 1997-01-31 1998-08-11 Zeria Pharmaceut Co Ltd Ｎ−置換ベンゾイルアミン誘導体、それを含有する医薬及び該化合物の製造中間体
US6197970B1 (en) * 1997-06-24 2001-03-06 Zeria Pharmaceutical Co., Ltd. Process for producing 2-hydroxybenzamide derivatives
US5981556A (en) * 1997-07-22 1999-11-09 G.D. Searle & Co. 1,3-diazolino and 1,3-diazolidino heterocycles as useful nitric oxide synthase inhibitors
KR20010080025A (ko) * 1998-11-23 2001-08-22 디르크 반테 소화불량 치료용 의약의 제조를 위한 프루칼로프라이드의용도
ATE256125T1 (de) * 1999-06-02 2003-12-15 Janssen Pharmaceutica Nv Aminoalkyl substituierte (benzodioxane, benzofurane oder benzopyrane) derivate
DE60025261T2 (de) * 1999-11-23 2006-08-24 Janssen Pharmaceutica N.V. Verwendung von 5ht3 antagonisten zur fundusentspannung
GB0002336D0 (en) * 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
JP4876367B2 (ja) * 2000-09-08 2012-02-15 ゼリア新薬工業株式会社 アミノチアゾール誘導体を有効成分とする大腸運動不全治療剤
US6986882B2 (en) * 2002-01-17 2006-01-17 Astrazeneca Ab Therapy for functional dyspepsia

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
The Journal of Pharmacology and Experimental Therapeutics, 294(1), pp. 33-37 (2000) *
The Journal of Pharmacology and Experimental Therapeutics, 294(1), pp. 33-37 (2000)*
대한소화관운동학회지, 6, pp. 235-240 (2000) *
대한소화관운동학회지, 6, pp. 235-240 (2000)*

Also Published As

Publication number Publication date
AU2003236326A1 (en) 2003-10-20
KR20120037035A (ko) 2012-04-18
JP5360075B2 (ja) 2013-12-04
EP1493441B1 (en) 2011-08-31
CN102125551B (zh) 2015-07-22
JP5281226B2 (ja) 2013-09-04
KR20050002925A (ko) 2005-01-10
EP2301540A1 (en) 2011-03-30
CN1646123A (zh) 2005-07-27
US20090156652A1 (en) 2009-06-18
SI1493441T1 (sl) 2011-12-30
PT1493441E (pt) 2011-09-28
ATE522214T1 (de) 2011-09-15
KR20110010837A (ko) 2011-02-07
US20150141475A1 (en) 2015-05-21
JP2011068692A (ja) 2011-04-07
US20050176788A1 (en) 2005-08-11
CY1112057T1 (el) 2015-11-04
ES2368732T3 (es) 2011-11-21
DK1493441T3 (da) 2011-10-17
EP1493441A4 (en) 2007-10-17
EP1493441A1 (en) 2005-01-05
AU2003236326B2 (en) 2008-02-28
CA2481916C (en) 2013-02-26
US20200375954A1 (en) 2020-12-03
KR20130101162A (ko) 2013-09-12
CA2481916A1 (en) 2003-10-16
CN102125551A (zh) 2011-07-20
WO2003084537A1 (en) 2003-10-16
JPWO2003084537A1 (ja) 2005-08-11

Similar Documents

Publication Publication Date Title
US20200375954A1 (en) Therapeutic agent for food competence disorder in stomach
KR101639821B1 (ko) 염증성 장질환 치료제
AU2013237881B2 (en) Dosage forms of halofuginone and methods of use
JP4415075B2 (ja) 炎症性腸疾患のためのカッパーアヘン製剤作働薬
RU2672248C1 (ru) Применение производного бензимидазола для лечения ночного кислотного прорыва
JP4876367B2 (ja) アミノチアゾール誘導体を有効成分とする大腸運動不全治療剤
JPH0152363B2 (enExample)
EA006776B1 (ru) Фармацевтическая композиция для лечения диабетической невропатии
JP5196641B2 (ja) 脊髄小脳変性症治療剤
JP2899740B2 (ja) 炎症性腸疾患治療剤
JP4598674B2 (ja) 統合失調症治療剤
JP5142991B2 (ja) １−（３−クロロフェニル）−３−アルキルピペラジンを含む食欲障害治療用医薬組成物
CN117157075A (zh) 步态障碍治疗剂
JPH0753363A (ja) 頻尿治療剤
CN107582556A (zh) 一种治疗消化性溃疡的药物复方制剂
CN111150735A (zh) 一种治疗尿酸性肾病的制剂
JPH07291861A (ja) 炎症性腸疾患予防治療剤

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20130827

Application number text: 1020127005319

Filing date: 20120228

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20131104

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20140619

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20140718

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20140721

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
J202 Request for trial for correction [limitation]
PJ0202 Trial for correction

Comment text: Request for Trial

Patent event date: 20140806

Patent event code: PJ02022R01D

Comment text: Registration of Establishment

Patent event date: 20140718

Patent event code: PJ02021E01I

Appeal kind category: Correction

Decision date: 20151127

Request date: 20140806

Appeal identifier: 2014105000075

J301 Trial decision

Free format text: TRIAL DECISION FOR CORRECTION REQUESTED 20140806

Effective date: 20151127

Free format text: TRIAL NUMBER: 2014105000075; TRIAL DECISION FOR CORRECTION REQUESTED 20140806

Effective date: 20151127

PJ1301 Trial decision

Patent event code: PJ13011S03D

Patent event date: 20151127

Comment text: Trial Decision on Correction (Patent, Utility Model)

Appeal kind category: Correction

Request date: 20140806

Decision date: 20151127

Appeal identifier: 2014105000075

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

Publication date: 20160202

FPAY Annual fee payment

Payment date: 20170616

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20170616

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20180615

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20180615

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20190617

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20190617

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20200618

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20200618

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20210617

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20210617

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20220615

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20220615

Start annual number: 9

End annual number: 9

PC1801 Expiration of term

Termination date: 20231008

Termination category: Expiration of duration